

18 November 2013

December 2013 Pharmaceutical Schedule Dispatch

This document is provided to pharmacists as an early notification of the changes to be announced in the **December 2013** Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50) to change or remove your contact details.

New listings

- Mesalazine (Pentasa) suppos 1 g, 30 pack size (p'code 2432218)
- Compound electrolytes (Enerlyte) powder for oral soln (p'code 2441292)
- Spironolactone (Spiractin) tab 25 mg (p'code 2435179) and 100 mg (p'code 2435187)
- Urea (healthE Urea Cream) crm 10%, 100 g OP (p'code 2444690)
- Oxytocin (Oxytocin BNM) inj 5 iu per ml, 1 ml ampoule (p'code 2448211) and 10 iu per ml, 1 ml ampoule (p'code 2448203)
- Lamivudine (Lamivudine Alphapharm) tab 150 mg (p'code 2444526) - Special Authority
- Ropinirole hydrochloride (Apo-Ropinirole) tab 0.25 mg (p'code 2443074), 1 mg (p'code 2443082), 2 mg (p'code 2443090) and 5 mg (p'code 2443104)
- Pramipexole hydrochloride (Ramipex) tab 0.25 mg (p'code 2450534) and 1 mg (p'code 2450542) – S29
- Gabapentin (Arrow-Gabapentin) cap 100 mg (p'code 2443848), 300 mg (p'code 2443856) and 400 mg (p'code 2443864)
- Olanzapine (Zypine) tab 2.5 mg (p'code 2439859), 5 mg (p'code 2439867) and 10 mg (p'code 2439875)
- Olanzapine (Zypine ODT) tab orodispersible 5 mg (p'code 2439832) and 10 mg (p'code 2439840)

Changes to restrictions, chemical names and presentations

- Compound electrolytes (Electral and Enerlyte) powder for soln for oral use 4.4 g – amendment of presentation description to powder for oral soln
- Enalapril maleate (Acetec) tab 5 mg, 10 mg and 20 mg – removal of Brand switch fee payable
- Cetomacrogol with glycerol (Pharmacy Health Sorbolene with Glycerin) amendments to unit of measure
- Oxytocin (Syntocinon and Oxytocin BNM) inj 5 iu per ml, 1 ml **ampoule** and inj 10 iu per ml, 1 ml **ampoule** – amendment of presentation description
- Carbimazole (Neo-Mercazole) tab 5 mg – removal of STAT symbol (temporary for stock management)
- Erythromycin ethyl succinate (E-Mycin) tab 400 mg and grans for oral liq 200 mg per 5 ml – amendment to PSO quantities and addition of RFPP
- Amoxicillin (Alphamox) cap 250 mg and 500 mg (Ospamox) grans for oral liq 250 mg per 5 ml – amendment to PSO quantities and addition of RFPP
- Phenoxymethylpenicillin (Penicillin V) cap potassium salt 500 mg (Cilicaine VK) grans for oral liq 250 mg per 5 ml (AFT) – amendment to PSO quantities and addition of RFPP
- Benzbromarone (Benzbromaron AL 100) tab 100 mg – addition of note to Special Authority

- Ropinirole hydrochloride – removal of certified exemption
- Naltrexone hydrochloride (Naltraccord) tab 50 mg – amendment to Special Authority
- Montelukast (Singulair) tab 4 mg, 5 mg and 10 mg – amendment to Special Authority

Decreased subsidy

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Clopidogrel	Tab 75 mg	Arrow - Clopid*	Apo-Clopidogrel
Tamsulosin hydrochloride	Cap 400 mcg	Tamsulosin-Rex (100 pack size)*	Tamsulosin-Rex (30 pack size)
Morphine Sulphate	Cap long-acting 10 mg, 30 mg, 60 mg and 100 mg	m-Eslon	
Loratadine	Tab 10 mg	Lorafix*	Loraclear Hayfever Relief

* no subsidy changes for these brands

Consultation on changing the dispensing frequency rule and adding zopiclone to the Safety Medicines List

The consultation sets out proposed amendments to the dispensing frequency rule for prescribing Class B controlled drugs or clozapine to patients in residential care.

The consultation also covers a proposal to add zopiclone to the Safety Medicines List to permit prescribers to determine the frequency of dispensing for zopiclone.

Further information on the consultation can be found on our website at

<http://www.pharmac.health.nz/news#consultation>